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MaBACKGROUND A recent meta-analysis demonstrated a survival beneﬁt in post-infarction patients whose ventricular
tachycardia (VT) was rendered noninducible by catheter ablation. Furthermore, patients with noninducible VT had a lower
VT recurrence rate than did patients whose VT remained inducible after ablation.
OBJECTIVES The purpose of this multicenter cohort study was to assess whether noninducibility after VT ablation is
independently associated with improved survival.
METHODS Data from 1,064 patients who underwent VT ablation for post-infarction VT at seven international centers
were analyzed. The ablation procedure was considered successful if no VT was inducible at the end of the procedure and
unsuccessful if VT remained inducible or if programmed stimulation was not performed at the end of the ablation.
RESULTS Median follow-up time was 633 days. Noninducibility was independently associated with lower mortality
(adjusted hazard ratio: 0.65; 95% conﬁdence interval: 0.53 to 0.79; p < 0.001). Atrial ﬁbrillation, diabetes, and age were
other independent predictors of higher mortality. Ablation of only the clinical VT in patients who also had inducible,
nonclinical VTs was not associated with improved survival.
CONCLUSIONS Noninducibility after VT ablation in patients with post-infarction VT is independently associated with
lower mortality during long-term follow-up. (J Am Coll Cardiol 2015;65:1954–9) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
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1955The purpose of this study was to assess whether
noninducibility of VT is an independent predictor of
improved survival after catheter ablation in patients
with post-infarction VT.SEE PAGE 1960
NYHA = New York
Heart Association
VT = ventricular tachycardiaMETHODS
Seven centers experienced in catheter ablation of VT
provided data from consecutive patients who under-
went VT ablation for post-infarction VT between 2004
and 2012. Baseline demographic and clinical data
were collected. Eligible patients had prior myocardial
infarction by history and objective testing.
MAPPING AND ABLATION. After informed consent
was obtained from each patient, a multipolar catheter
was positioned in the right ventricle. Programmed
ventricular stimulation was performed from multiple
sites in an attempt to induce VT. The induced VTs
were compared to each patient’s clinical VT using 12-
lead electrocardiograms whenever available or the
electrogram morphology of VT episodes recorded by
an implantable cardioverter-deﬁbrillator. If these
were unavailable, the cycle lengths of the clinical and
induced VTs were compared. The protocol of pro-
grammed stimulation included up to 4 extra stimuli
from 2 ventricular locations with coupling intervals
down to 200 ms or refractoriness, whichever occurred
ﬁrst. An irrigated-tip catheter was used for mapping
and ablation in conjunction with a 3-dimensional
mapping system. If the VT was hemodynamically
tolerated, entrainment mapping was performed and
radiofrequency energy was delivered at sites with
concealed entrainment. In the case of hemodynami-
cally unstable VT, ablation was performed during si-
nus rhythm in areas with matching pace-maps or
areas with fragmented electrograms. Post-ablation,
programmed ventricular stimulation was repeated
using the same stimulation protocol.
The procedure was classiﬁed as successful if no
sustained VT (lasting $30 s or requiring termination)
was inducible when pacing was performed from 2
ventricular sites with up to 4 extra stimuli. The
procedure was considered unsuccessful if any clin-
ical or nonclinical sustained, monomorphic VT was
inducible or if programmed stimulation was not
performed at the end of the ablation procedure. The
latter was “unsuccessful” because programmed
ventricular stimulation was not performed at pro-
cedure completion if patients were unstable. If VT
was not inducible at the beginning of the procedure
and remained noninducible at the conclusion of the
procedure, an ablation was not considered successful.
For sensitivity analysis, we also assessed therelationship between noninducibility of VT
post-ablation and mortality after excluding
patients whose VT was noninducible before
ablation. Induction of only polymorphic VT or
ventricular ﬁbrillation at the end of the pro-
cedure was not considered as a failed ablation
procedure.After the ablation procedure, treatment with anti-
arrhythmic medications was at the discretion of the
attending physician. Follow-up data were obtained
from the implantable cardioverter-deﬁbrillator clinics
or from the referring physician.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Comparisons of baseline
demographic, clinical, and procedure-related char-
acteristics between patients with noninducible VT
post-ablation versus patients with inducible VT
(or in whom inducibility was not tested after ablation)
were performed using the Fisher exact test or chi-
square test, as appropriate for discrete variables,
and the 2-group Student t test for continuous vari-
ables. For mortality comparisons, time-to-event ana-
lyses were done. Log-rank tests were done to assess
the relationship between each baseline variable and
mortality. A Kaplan–Meier survival curve was plotted
by noninducibility versus inducibility of VT or
inability to perform stimulation post-ablation. Cox
regression was used to assess whether successful
ablation was independently associated with mortality
after adjustment for other baseline variables that
were either associated with a p value <0.1 on bivar-
iate analyses or known to be associated with mortal-
ity. Robust standard errors were used to adjust for
potential correlation of outcomes within each study
center. Nonproportional hazards were checked by
including an interaction term of time by non-
inducibility post-ablation in the Cox model. For
robustness of the ﬁnding, we also obtained an esti-
mate stratiﬁed by study center, which allows for
different baseline hazards for each study center.
Results are reported as hazard ratios (HRs) with
95% conﬁdence intervals (CIs). Analyses were done
using Stata 13.1 (StataCorp LP, College Station,
Texas). A p value <0.05 was considered statistically
signiﬁcant.
RESULTS
Data from a total of 1,064 consecutive patients from
seven centers were included in the study (Table 1).
Data regarding inducibility at onset were available in
1,011 patients and, of these, VT was inducible in 948
patients (93.8%). Radiofrequency energy was deliv-
ered for a mean of 50  44 min (range 1.1 to 253 min),
TABLE 1 Patient Characteristics
Study Groups
All Patients
(N ¼ 992)
Inducible or No
Stimulated Procedure
After Ablation
(n ¼ 349)
Noninducible
(n ¼ 643)
p
Value
Age, yrs 67.9  9.2 68.1  9.8 0.71 68.1  9.6
Male 94 93 0.4 94
LVEF 30.3  11.3 31.5  11.5 0.12 31.1  11.4
Risk factors
Heart failure 86.5 84.9 0.52 85.4
Hypertension 75.4 76.7 0.63 76.3
History of AF 38.9 38.0 0.81 38.3
CRI 37.0 38.7 0.63 38.1
Diabetes 30.1 29.7 0.91 29.9
PVD 16.4 17.3 0.73 17.0
COPD 15.3 14.7 0.80 14.9
VT history
VT storm 30.1 30.8 0.81 30.6
Incessant VT 17.5 18.3 0.74 18.0
Values are mean  SD or %. Data listed at the procedure’s end for patients included in the mortality analysis
(N ¼ 998).
AF ¼ atrial ﬁbrillation; COPD ¼ chronic obstructive lung disease; CRI ¼ chronic renal insufﬁciency; LVEF ¼ left
ventricular ejection fraction; PVD ¼ peripheral vascular disease; VT ¼ ventricular tachycardia.
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1956and the mean procedure duration was 236  136 min
(range 50 to 755 min). At the conclusion of the pro-
cedure, programmed stimulation was not repeated in
106 patients, and no VTs were inducible in 663
patients. Of the 948 patients with VTs inducibleow
VT ablation performed
1,064 patients
Incomplete data at onset: n=53
1,011 patients
Patients with inducible VT:
948 patients
VT ablation
906 patients
Noninducible post-ablation:
n=603
lation:
Incomplete data about ablation
outcome: n=42
VT not inducible at onset: n=63
nts undergoing ventricular tachycardia (VT) ablation is shown.
cal testing after ablation, nearly twice as many patients werebefore the ablation procedure, VT was no longer
inducible after ablation in 603 patients. In 254 pa-
tients, the clinical VT was no longer inducible, but
other nonclinical VTs remained inducible. The pro-
cedure failed in 49 patients in whom the clinical VT
remained inducible (Figure 1).
Mortality analysis included data from 998 patients,
after the exclusion of 24 patients without mortality
data and 42 patients with missing data regarding both
the success of the ablation procedure and whether
programmed stimulation was performed at the end of
the ablation. Patients were at risk for a total of
700,367 days, with a median of 634 days per patient.
Of the 998 patients, VT was noninducible after the
ablation in 649 patients. Median survival time was
1,467 days (48.1 months) in patients with non-
inducible VT versus 1,349 days (44.2 months) in pa-
tients with inducible VT or in whom programmed
stimulation was not performed at the conclusion of
the procedure. The difference corresponded to an
estimated 4.7 months of life gained at 6 years. The
patients whose VT was noninducible had a 0.77-fold
(95% CI: 0.61 to 0.97) lower risk for death compared
with patients in whom VT remained inducible or in
whom programmed stimulation was not performed.
Kaplan-Meier survival curves were signiﬁcantly
different between the groups (log-rank: p ¼ 0.02)
(Central Illustration).
Exclusion of the 51 patients whose VT was non-
inducible at the onset of the procedure did not change
the results with respect to improved survival in the
patients with noninducible VT. Speciﬁcally, in the
subset of patients whose VT was rendered non-
inducible, mortality was lower compared with that in
the group in whom VT was still inducible or pro-
grammed stimulation was not performed (HR: 0.79;
95% CI: 0.63 to 0.99). With respect to mortality, in 295
patients in whom data were available regarding
whether the clinical VT was ablated, successfully
ablated clinical VT was associated with a numerically
lower hazard, but the HR was not signiﬁcantly lower
than 1.0 (HR: 0.70; 95% CI: 0.33 to 1.49).
The group whose VT was rendered noninducible
had signiﬁcantly greater freedom from VT re-
currences compared with that in the group in whom
VT remained inducible (61.3% vs. 45.4%, respec-
tively; p < 0.001). The group in whom the clinical VT
was ablated but other VTs remained inducible had a
recurrence rate similar to that in the group in which
the clinical VT remained inducible (56% vs. 55%;
p ¼ 0.92). On unadjusted analysis, VT recurrence was
not predictive of mortality (HR: 1.20; 95% CI: 0.77 to
1.88; p ¼ 0.42). No difference was found in mortality
between those 51 patients (5.1%) whose VT was not
CENTRAL ILLUSTRATION Survival in Patients With Ablated VT
Yokokawa, M. et al. J Am Coll Cardiol. 2015; 65(18):1954–9.
Analysis Time in Months
In patients who have experienced a myocardial infarction, catheter ablation can render ventricular tachycardia (VT) noninducible and produce lower VT recurrence rates
than in patients who remain inducible. The left panel illustrates catheters positioned in the right ventricle for programmed stimulation and in the left ventricle for
ablation of VT with in scar tissue. The right panel shows the Kaplan-Meier survival curve for those with noninducible VT compared with those with inducible VT or in
whom programmed stimulation was not performed. Noninducibility post-ablation was independently associated with lower mortality (log-rank: p ¼ 0.02).
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1957inducible at baseline and patients with inducible VT
(HR: 0.93; 95% CI: 0.42 to 2.06; p ¼ 0.85). Not per-
forming programmed stimulation after ablation was
not signiﬁcantly associated with higher mortality
(HR: 1.23; 95% CI: 0.84 to 1.82; p ¼ 0.28).
Before the ablation procedure, 583 of 1,064 pa-
tients (55%) were on amiodarone. Post-ablation, 473
patients were on amiodarone (44%) and 118 patients
were on sotalol (11%). A total of 924 patients (88%)
were discharged on beta-blocker therapy. Patients
with inducible VT were more likely to have been
discharged on amiodarone compared with patients
whose VT was noninducible at the end of the ablation
procedure (56% vs. 37%; p < 0.0001). This was not the
case for sotalol, which was used in 10% of the patients
whose VT was noninducible compared with 13% of
the patients whose VT continued to be inducible at
the end of the ablation (p ¼ 0.21). Finally, use of post-
ablation amiodarone was more prevalent in patients
with a history of atrial ﬁbrillation (AF) than in pa-
tients without AF (49% vs. 41%; p ¼ 0.02).
Atrial ﬁbrillation, New York Heart Association
(NYHA) functional class, ejection fraction, hyperlip-
idemia, diabetes, and chronic renal failure were allassociated with increased mortality by bivariate
analysis, as were VT inducibility post-ablation and
advanced age (Table 2). By multivariate analysis,
advanced age (HR: 1.03), a history of AF (HR: 1.83),
and a history of diabetes (HR: 1.58) were indepen-
dently associated with increased mortality post-
ablation. Noninducibility of VT post-ablation was
independently associated with a lower mortality (HR:
0.65). Noninducibility of VT post-ablation was inde-
pendently predictive of survival (HR: 0.72; 95% CI:
0.54 to 0.96; p ¼ 0.03), even in the subgroup
excluding patients in whom programmed stimulation
was not performed post-ablation. Although NYHA
functional class did not inﬂuence mortality on
multivariate analysis, increased NYHA functional
class was associated with an increased mortality, with
an adjusted HR of 1.68 for NYHA functional class III
versus I and an adjusted HR of 1.77 for NYHA func-
tional class IV versus I, after control for other cova-
riates and noninducibility. No adjustment for VT
recurrence was performed in the main Cox regression
model (Table 2) because time-to-recurrence data were
not available to appropriately adjust for its time-
varying nature. However, in another Cox model in
TABLE 2 Adjusted HR Mortality Estimates
HR 95% CI p Value
Age 1.03 1.01–1.06 0.001
Noninducible post-ablation* 0.65 0.53–0.79 <0.001
NYHA functional class†
II 0.89 0.39–2.03 0.78
III 1.68 0.79–3.56 0.18
IV 1.77 0.69–4.54 0.24
History of AF 1.83 1.14–2.93 0.01
Diabetes 1.58 1.17–2.13 <0.01
Noninducible at onset 0.54 0.29–1.01 0.06
Incessant VT 1.31 1.09–1.57 <0.01
Cox regression model (n ¼ 671; included patients in whom all data were available
for analysis). *Compared with inducible or no stimulation performed post-ablation.
†Reference ¼ I.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NYHA ¼ New York Heart
Association; other abbreviations as in Table 1.
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1958which VT recurrence was added as a time-ﬁxed co-
variate, along with other patient characteristics, the
adjusted HR estimate remained similar to that of
the main model for noninducibility post-ablation
(HR: 0.69; p ¼ 0.002) and other covariates, while
VT recurrence was marginally signiﬁcant (HR: 1.5;
p ¼ 0.05).
Proportional hazards assumption was checked and
considered met, as indicated by the lack of evidence
for a signiﬁcant interaction of time by noninducibility
(p ¼ 0.09). Cox model stratiﬁed by study center
yielded an adjusted HR estimate for noninducibility
of VT post-ablation of 0.66 (95% CI: 0.46 to 0.95;
p ¼ 0.03), which was similar to the adjusted HR ac-
counting for within–study center correlation using
robust standard errors.
DISCUSSION
Noninducibility of VT post-ablation in this large-
scale, multicenter cohort of patients with prior
myocardial infarction who underwent VT ablation
was independently associated with lower mortality
(Central Illustration). Ablation of only the clinical VT
was not associated with a reduction in either mor-
tality or recurrent VT.
A recent meta-analysis demonstrated an associa-
tion of noninducibility after VT ablation procedures
with better survival (1). The ﬁndings from the present
cohort study support the ﬁndings of the meta-
analysis and identify other factors associated with
higher mortality, including AF and diabetes. These
factors have been described in a prior report (2). Most
likely, these factors contribute to mortality through
progression of the underlying cardiac disease process,
or they may be markers of disease severity. VT
recurrence is associated with a higher risk for death,and the association of an effective VT ablation pro-
cedure with lower mortality in the present study
supports a potential contribution of VT recurrence to
mortality. Further studies, however, are necessary to
conﬁrm that lower mortality is indeed due to a lower
VT recurrence. The difference in mortality becomes
apparent only after 1 year of follow-up, which could
be why studies with smaller sample sizes and shorter
follow-up durations did not detect a mortality beneﬁt
after VT ablation (2).
Although the ﬁndings from the prior meta-analysis
suggested that ablation of the clinical VT also reduced
VT recurrence (1), this idea could not be conﬁrmed in
the present study. However, elimination of the clin-
ical VT appears to be beneﬁcial, as indicated by a
numerically low HR, although this ﬁnding was not
statistically signiﬁcant, likely due to the small sample
size. In a recent consensus statement (3), eliminating
the clinical VT was recommended as a minimal goal,
with the idea that abolition of recurrent, spontane-
ously occurring VTs results in a decrease of the
arrhythmia burden in most patients. This issue re-
mains complex because most patients have multiple
morphologies of inducible VT, and whether those that
have not been observed to occur spontaneously,
referred to as nonclinical, should be targeted for
ablation is controversial. Conﬁrmation that an abla-
ted VT actually was a clinical VT may be difﬁcult
because a 12-lead electrocardiogram of the clinical
VT is rarely available at the time of the ablation pro-
cedure. The VT cycle length has been used as a sur-
rogate for QRS morphology, but a prior study
has demonstrated that different VTs can have iden-
tical cycle lengths, making it impossible to distin-
guish clinical from nonclinical VTs (4). Therefore, the
assumption that the clinical VT has been eliminated
might also be erroneous. Larger-scale studies are
required to establish the value of targeting and
ablating only the clinical VT.
A prior study that assessed the outcome of VT
ablation reported that heart failure was associated
with increased mortality (2). Although we were not
able to demonstrate that NYHA functional class was
associated with a statistically signiﬁcant increase in
mortality after adjusting for other covariates, our data
are consistent with those from published results
showing an adjusted hazard of mortality of about
70% higher for NYHA functional classes III and IV
compared to NYHA functional class I.
Even patients whose VT is rendered noninducible
after ablation continue to have an appreciable rate of
recurrent VT; hence, the value of programmed stim-
ulation has been debated (5). Several factors might
contribute to VT recurrence after an apparently
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In patients with
post-infarction VT, inability to induce VT post-ablation is asso-
ciated with improved survival compared to patients in whom VT
remains inducible, supporting elimination of inducible VTs as an
appropriate endpoint for VT ablation procedures.
TRANSLATIONAL OUTLOOK: Better characterization of re-
entry circuits in the infarct zone may reduce recurrence of VT and
improve the clinical outcomes associated with post-infarction VT
ablation procedures.
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1959successful ablation procedure. A new VT substrate
may emerge with further evolution of the infarct re-
gion and ventricular remodeling (6). Alternately, a VT
may not have been inducible during the index proce-
dure, resulting in no ablation to an area of arrhyth-
mogenic scar (6). More thorough ablation has been
associated with an incremental beneﬁt with respect to
VT recurrence when areas of late potentials were ab-
lated in addition to rendering a patient’s VT non-
inducible (7). Another mechanism of VT recurrence
despite an apparently successful ablation rendering
all VTs noninducible is a transient effect due to local
edema induced by radiofrequency ablation. Once the
edema resolves, VT may recur (8). Therefore, non-
inducibility of VT is not a perfect endpoint. However,
because it is associated with decreased mortality, it
does seem to be a desirable endpoint.
STUDY LIMITATIONS. Although the ﬁndings from
the present study support attempts to achieve non-
inducibility of all monomorphic VTs, we cannot rule
out the possibility that noninducibility post-ablation
is a marker of less severe heart disease. Patients in
whom programmed stimulation was not repeated
post-ablation were pooled with the inducible group.
Consistent results after excluding these patients
from the analysis give us conﬁdence in our ﬁndings,
but it remains to be determined whether another
procedure, once a patient is more stable, can help to
further reduce VT recurrence in patients deemed
too unstable to undergo programmed stimulation
post-ablation. Antiarrhythmic drug therapy was left
to the treating physicians and might have affected
the outcomes. Due to the retrospective design of
the study, the protocol of programmed stimula-
tion was not identical at all centers; however, allcenters did perform programmed stimulation from
2 ventricular sites with up to 4 extra stimuli and
coupling intervals down to 200 ms or refractoriness,
whichever occurred ﬁrst. Data on the impact of the
number of inducible VTs were not analyzed, and data
on the timing of VT recurrence were not available.
CONCLUSIONS
Noninducibility of VT after an ablation procedure
is independently associated with lower mortality
in patients with prior myocardial infarction. These
ﬁndings support the elimination of all inducible
monomorphic VTs as an endpoint of post-infarction
VT ablation.
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